We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Novel Blood Test for Myocardial Infarction Tested

By LabMedica International staff writers
Posted on 19 Jun 2019
The level cardiac myosin-binding protein C (cMyC) in the blood increase more rapidly after a myocardial infarction, and to a higher extent, than troponin. More...
This means meaning that the new test can rule out a myocardial infarction in a higher proportion of patients straight away.

Under current UK guidelines, people suspected of having a myocardial infarction are tested for high blood troponin levels as soon as they arrive in an Accident and Emergency department (A&E), and again after three hours. Depending on the type of troponin test used, up to 85% of people will need to remain in hospital for further tests in order to rule out a heart attack.

An international team of scientists working with King’s College London (London, UK) took blood from 776 patients traveling to hospital by ambulance in Denmark. In patients who did experience myocardial infarction, the protein was present in high enough concentrations 95% of the time for an on-the spot diagnosis. Importantly, the cMyC test outperformed the existing troponin test, which was only capable of diagnosing around 40% of patients in this way.

The cMyC blood test, developed by a team from King’s College London and tested across Europe, has already been shown to rapidly rule out a heart attack in more people than the standard troponin test. The team hopes to work with industry to create a portable testing device to be used in UK A&E departments. The test could also be used in ambulances in countries where ambulances have to drive considerable distances to get patients to their nearest hospital. The press release states that a simple handheld device could replace the time-consuming processes involved in sending samples to the hospital labs for analysis.

Tom Kaier, MD, PhD, a lead author of the study, said, “It is important for both patients and doctors to work out early who has had a heart attack and who has not. Now that we know that this test is sensitive enough to give an almost immediate heart attack diagnosis, we need to work on developing a testing device. We’d love to see this used in A&E departments within the next five years.” The study was presented at the British Cardiovascular Society Conference held June 4-6, 2019, in Manchester, UK.

Related Links:
King’s College London


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
HPV Test
Allplex HPV28 Detection
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:(L to R) Co-first author Yuan Feng, PhD, corresponding author Xiaotu Ma, PhD, and co-first author Hanxia Li, PhD, all of the St. Jude Department of Computational Biology. (Photo courtesy of St. Jude Children\'s Research Hospital)

Genomic Profiling Predicts Relapse Risk by Subtype in Pediatric Leukemia

B-cell acute lymphoblastic leukemia (B-ALL) is the most common childhood cancer, with more than 90% of patients surviving with modern treatments. Outcomes are worse when the disease returns, however, making... Read more

Hematology

view channel
Image: The newly certified products are the CytoCell ATM Deletion FISH Probe, CytoCell IGH Plus Breakapart FISH Probe, CytoCell IGH/FGFR3 Plus Translocation, Dual Fusion FISH Probe, and CytoCell IGH/MYEOV Plus Translocation, Dual Fusion FISH Probe. (Photo courtesy of OGT)

Newly Certified FISH Probes Support Cytogenetic Testing in Blood Cancers

Hematological malignancies such as non-Hodgkin lymphoma, acute lymphoblastic leukemia, chronic lymphoid leukemia, and multiple myeloma require assessment of key cytogenetic abnormalities.... Read more

Immunology

view channel
Image: Study design and collection of lower respiratory tract lining fluid (RTLF) using the PExA instrument. (Aguilera K, Hober A, Greilert Norin N, et al. eBioMedicine, 2026. doi:10.1016/j.ebiom.2026.106538)

Exhaled Breath Particles Reveal Virus-Specific Antibodies in the Lower Airways

Respiratory viruses such as influenza virus, SARS-CoV-2, and respiratory syncytial virus (RSV) require immune protection across the airway mucosa. Antibodies in the respiratory tract lining are important... Read more

Microbiology

view channel
Image: Four-quadrant streaking of fecal samples on chromogenic UTI agar shows various patterns of relative bacterial species abundance. The assorted shapes of the pinkish colonies indicate different E. coli strains. (Photo courtesy of Sokurenko Lab)

Stool Testing Predicts UTI Risk and Guides Antibiotic Selection

Urinary tract infections (UTIs) are a common reason for antibiotic prescribing in general medical practice and can be painful in postmenopausal women, sometimes progressing to kidney infection or life-threatening... Read more

Pathology

view channel
AI: Artificial intelligence; CNN: Convolutional neural networks; ResNet: Residual neural network. (Xing-hua Gao from The First Hospital of China Medical University, China Image Source Link: https://www.ovid.com/jnls/cmj/fulltext/10.1097/cm9.0000000000004154~deep-learning-based-computational-pathology-technologies)

Review Highlights Progress and Validation Needs for AI in Digital Pathology

Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read more

Industry

view channel
Image: Onvaro’s commercial portfolio will be anchored by the binx io platform, an FDA-cleared, CLIA-waived molecular point-of-care system with more than 1,000 installed instruments. (Photo courtesy of binx health)

New Diagnostics Company Onvaro Formed to Expand Decentralized Testing

Sapphiros, a diagnostics platform backed by investment funds managed by KKR, and binx health, a point-of-care diagnostics company backed by Hildred, have combined to form Onvaro. The new diagnostics company... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.